ChromaDex Co. (NASDAQ:CDXC) Shares Bought by International Assets Investment Management LLC

International Assets Investment Management LLC raised its stake in ChromaDex Co. (NASDAQ:CDXC) by 43.0% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 28,600 shares of the company’s stock after purchasing an additional 8,600 shares during the quarter. International Assets Investment Management LLC’s holdings in ChromaDex were worth $410,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of CDXC. Silverberg Bernstein Capital Management LLC acquired a new position in ChromaDex in the fourth quarter valued at about $118,000. Gamco Investors INC. ET AL lifted its position in ChromaDex by 26.5% in the third quarter. Gamco Investors INC. ET AL now owns 259,850 shares of the company’s stock valued at $379,000 after buying an additional 54,500 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in ChromaDex by 121.9% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 83,031 shares of the company’s stock valued at $121,000 after buying an additional 45,618 shares during the last quarter. Finally, Gabelli Funds LLC lifted its position in ChromaDex by 9.1% in the third quarter. Gabelli Funds LLC now owns 180,000 shares of the company’s stock valued at $263,000 after buying an additional 15,000 shares during the last quarter. Institutional investors and hedge funds own 15.41% of the company’s stock.

Wall Street Analysts Forecast Growth

CDXC has been the topic of several research reports. Roth Mkm increased their price target on shares of ChromaDex from $4.25 to $6.00 and gave the stock a “buy” rating in a research report on Tuesday, April 9th. StockNews.com initiated coverage on shares of ChromaDex in a research report on Sunday, March 3rd. They set a “strong-buy” rating on the stock.

ChromaDex Stock Performance

Shares of CDXC opened at $3.39 on Friday. The stock has a market capitalization of $255.30 million, a PE ratio of -48.42 and a beta of 1.99. ChromaDex Co. has a 1 year low of $1.25 and a 1 year high of $4.65. The company’s 50-day simple moving average is $2.85 and its 200-day simple moving average is $1.92.

ChromaDex Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.